Table 1. Demographic and disease characteristics at baseline of patients with advanced hepatocellular carcinoma.
| Variable | Apatinib group (n=26) [cases (%)] | Sorafenib group (n=46) [cases (%)] | P |
|---|---|---|---|
| Sex, female/male | 2/24 (7.7/92.3) | 2/44 (4.3/95.7) | 0.552 |
| Age, years | 48.1 [42.3, 53.0] | 52.6 [44.8, 61.9] | 0.161 |
| Hepatitis | 0.444 | ||
| None | 5 (19.2) | 4 (8.7) | |
| HBV | 21 (80.8) | 40 (87.0) | |
| HCV | 0 | 1 (2.2) | |
| HBV + HCV | 0 | 1 (2.2) | |
| ALB, g/L | 43.6 [41.2, 45.4] | 42.1 [38.9, 45.1] | 0.260 |
| TBIL, µmol/L | 15.8 [10.3, 21.9] | 14.0 [11.6, 15.8] | 0.218 |
| PT, s | 12.5 [12.1, 12.5] | 12.5 [12.5, 12.5] | 0.155 |
| AFP, ng/mL | 39.8 [6.8, 765.6] | 39.8 [15.0, 1,069.0] | 0.596 |
| Tumor number | 0.499 | ||
| 1 | 4 (15.4) | 11 (23.9) | |
| 2 | 0 | 1 (2.2) | |
| ≥3 | 22 (84.6) | 34 (73.9) | |
| Tumor size (cm) | 6.1 [2.4, 9.7] | 5.8 [2.6, 9.0] | 0.731 |
| BCLC stage, B/C | 6/20 (23.1/76.9) | 11/35 (23.9/76.1) | 0.936 |
| Vascular invasion, no/yes | 14/12 (53.8/46.2) | 26/20 (56.5/43.5) | 0.826 |
| Extrahepatic metastasis, no/yes | 11/15 (42.3/57.7) | 21/25 (45.7/54.3) | 0.784 |
Values are presented as the median [IQR] or n (%). AFP, alpha-fetoprotein; ALB, albumin; BCLC stage, Barcelona clinic liver cancer stage; HBV, hepatitis B virus; HCV, hepatitis C virus; TBIL, total bilirubin; PT, prothrombin time.